Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were...
Italy starts probe into Lucentis biosimilar delay allegation
Novartis, Roche unit and others face Italy antitrust probe over eye drug
iTeos Therapeutics’ $120M offering: The immuno-oncology company is selling about 1.1 million shares for $17.50 apiece. RA Capital Management and Boxer Capital — both existing investors — are leading the financing. iTeos added that its Phase 2 test of belrestotug plus dostarlimab in metastatic PD-L1 high non-small cell lung cancer “exceeded pre-defined efficacy criteria” at an interim assessment. Its stock $ITOS was up about 40% on Friday morning. — Jaimy Lee & Ayisha Sharma
Xbrane provides reg update on FDA review of its ranibizumab biosimilar candidate
Genentech`s Biologic Lucentis (ranibizumab) Receives Approval in the U.S.
Lucentis biosimilar Cimerli is the best-selling product for Coherus BioSciences, accounting for 54% of its revenue in the third quarter of last year.
CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* Demonstrated safety and efficacy in clinical trials and real-world settings Robust and reliable supply...
Ranibizumab Launch Midas Pharma is the Marketing Authorisation Holder (MAH) of a biosimilar
The FDA has rejected Outlook Therapeutics’ ophthalmic formulation of bevacizumab for wet AMD, an eye disorder that can cause blurred vision or blind spots.